{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:07:35Z","timestamp":1784696855921,"version":"3.55.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background and objective<\/jats:title>\n                    <jats:p>Renal angiomyolipomas associated with tuberous sclerosis complex (TSC-RAML) may lead to progressive renal damage and hemorrhage. Everolimus is recommended as first-line therapy, but predictors of treatment response and optimal dosing strategies remain unclear. We aimed to evaluate the efficacy of everolimus and to determine whether tumor fat composition predicts treatment response, as well as whether a reduced-dose regimen provides comparable outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicenter prospective cohort study conducted across multiple centers in China, 183 consecutive patients with TSC-RAML were enrolled. Three prespecified, outcome-specific analytical subsets were generated from the overall cohort according to the data required for each analysis: (1) standard-dose everolimus efficacy analysis, (2) CT-based tumor fat-composition analysis, and (3) exploratory dose-comparison analysis. Radiographic evaluations were performed at baseline, 3 months, and 6 months. The primary outcome was the RAML response rate, defined as \u226550% reduction in target tumor volume.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings and limitations<\/jats:title>\n                    <jats:p>A \u226550% reduction in tumor volume occurred in 44% (34\/78) of patients at 3 months and 83% (60\/72) at 6 months. Tumor reduction was significantly greater in fat-poor than in fat-rich lesions. No significant difference in response was observed between the standard- and low-dose groups. Oral mucositis was the most common adverse event but occurred less frequently in the low-dose group (P\u00a0= .002). Tumor regrowth was observed after treatment discontinuation. Limitations include the nonrandomized design, in which dose selection was based on clinical criteria from previously published protocols, unequal group sizes in the dose-comparison analysis, and the open-label nature of treatment administration, which may introduce selection and ascertainment bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and clinical implications<\/jats:title>\n                    <jats:p>In this large Chinese cohort of patients with TSC-RAML, everolimus effectively reduces tumor volume, particularly in fat-poor lesions. CT-derived tumor fat composition may help predict treatment response. In this exploratory cohort, low-dose everolimus showed promising short-term activity with potentially improved tolerability, but randomized studies are needed to confirm comparative efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1893155","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:48:00Z","timestamp":1784695680000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor fat composition predicts response to everolimus and supports low-dose therapy in TSC-associated renal angiomyolipomas: a multicenter prospective study"],"prefix":"10.3389","volume":"16","author":[{"given":"Ke","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Urology, Xi\u2019an People\u2019s Hospital (Xi\u2019an Fourth Hospital), School of Medicine, Northwest University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfei","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Urology, Xi\u2019an People\u2019s Hospital (Xi\u2019an Fourth Hospital), School of Medicine, Northwest University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biqi","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Scientific, Xi\u2019an People\u2019s Hospital (Xi\u2019an Fourth Hospital), School of Medicine, Northwest University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boxin","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Urology, Xi\u2019an People\u2019s Hospital (Xi\u2019an Fourth Hospital), School of Medicine, Northwest University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiping","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Urology, Xi\u2019an People\u2019s Hospital (Xi\u2019an Fourth Hospital), School of Medicine, Northwest University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Urology, Xi\u2019an People\u2019s Hospital (Xi\u2019an Fourth Hospital), School of Medicine, Northwest University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulin","family":"Chen","sequence":"additional","affiliation":[{"name":"Laboratory of Tissue Engineering, College of Life Sciences, Northwest University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Xi\u2019an People\u2019s Hospital (Xi\u2019an Fourth Hospital), School of Medicine, Northwest University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, Xi\u2019an People\u2019s Hospital (Xi\u2019an Fourth Hospital), School of Medicine, Northwest University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Urology, Xi\u2019an People\u2019s Hospital (Xi\u2019an Fourth Hospital), School of Medicine, Northwest University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16035","DOI":"10.1002\/ajmg.c.31638","article-title":"Tuberous sclerosis complex","volume":"2","author":"Henske","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","article-title":"Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations","volume":"123","author":"Northrup","year":"2021","journal-title":"Pediatr Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-019-02003-1","article-title":"An update on the central nervous system manifestations of tuberous sclerosis complex","volume":"139","author":"Cotter","year":"2020","journal-title":"Acta Neuropathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3109\/9780203997352.259","article-title":"Tuberous sclerosis","volume":"130","author":"Kwiatkowski","year":"1994","journal-title":"Arch Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1991.tb37754.x","article-title":"Epidemiology of tuberous sclerosis","volume":"615","author":"Osborne","year":"1991","journal-title":"Ann N Y Acad Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/6.12.2155","article-title":"Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis","volume":"6","author":"Jones","year":"1997","journal-title":"Hum Mol Genet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0025-6196(12)61196-3","article-title":"Causes of death in patients with tuberous sclerosis","volume":"66","author":"Shepherd","year":"1991","journal-title":"Mayo Clin Proc"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2004.05046.x","article-title":"An epidemiological study of renal pathology in tuberous sclerosis complex","volume":"94","author":"O'Callaghan","year":"2004","journal-title":"BJU Int"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000320891","article-title":"Tuberous sclerosis complex renal disease","volume":"118","author":"Dixon","year":"2011","journal-title":"Nephron Exp Nephrol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.urology.2015.12.009","article-title":"Evolving strategies in the treatment of tuberous sclerosis complex-associated angiomyolipomas (TSC-AML)","volume":"89","author":"Kapoor","year":"2016","journal-title":"Urology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00213-7","article-title":"Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy","volume":"21","author":"Curatolo","year":"2022","journal-title":"Lancet Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-02402-7","article-title":"The role of TSC1 and TSC2 proteins in neuronal axons","volume":"29","author":"Karalis","year":"2024","journal-title":"Mol Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1513\/annalsats.202012-1576ed","article-title":"TSC1 and TSC2 genotype in tuberous sclerosis complex: are other manifestations of this multisystem disease affected by genotype","volume":"18","author":"Darling","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"B14","doi-asserted-by":"publisher","first-page":"14337","DOI":"10.1038\/s41598-019-49814-6","article-title":"Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy","volume":"9","author":"Ni","year":"2019","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2015.10.002","article-title":"Genotype\/phenotype correlations in tuberous sclerosis complex","volume":"22","author":"Curatolo","year":"2015","journal-title":"Semin Pediatr Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9820181","article-title":"Recent advances and challenges of mTOR inhibitors use in the treatment of patients with tuberous sclerosis complex","volume":"2017","author":"Palavra","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1042\/bj20080281","article-title":"The TSC1-TSC2 complex: a molecular switchboard controlling cell growth","volume":"412","author":"Huang","year":"2008","journal-title":"Biochem J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1749-6632.2009.05117.x","article-title":"The tuberous sclerosis complex","volume":"1184","author":"Orlova","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0552-9","article-title":"The role of mTOR inhibitors in the treatment of patients with tuberous sclerosis complex: evidence-based and expert opinions","volume":"76","author":"Curatolo","year":"2016","journal-title":"Drugs"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.acuroe.2021.03.007","article-title":"Renal angiomyolipoma and tuberous sclerosis complex: long-term safety and efficacy outcomes of Everolimus therapy","volume":"45","author":"Ruiz Guerrero","year":"2021","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.02.037","article-title":"Commentary on: everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"82","author":"Black","year":"2013","journal-title":"Urology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180939","article-title":"Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study","volume":"12","author":"Bissler","year":"2017","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-024-00818-0","article-title":"Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group","volume":"20","author":"Mekahli","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"B24","article-title":"Declaration of helsinki","volume":"2","author":"Gandevia","year":"1964","journal-title":"Med J Aust"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01792-w","article-title":"Efficacy and safety of low-dose everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex","volume":"26","author":"Hatano","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.211.1.r99ap15283","article-title":"Abdominal fat: standardized technique for measurement at CT","volume":"211","author":"Yoshizumi","year":"1999","journal-title":"Radiology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-020-02755-5","article-title":"Fully automated CT imaging biomarkers of bone, muscle, and fat: correcting for the effect of intravenous contrast","volume":"46","author":"Perez","year":"2021","journal-title":"Abdom Radiol (NY)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.06.119","article-title":"Imaging characteristics of minimal fat renal angiomyolipoma with histologic correlations","volume":"66","author":"Hafron","year":"2005","journal-title":"Urology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.media.2019.101541","article-title":"Computer-aided detection and visualization of pulmonary embolism using a novel, compact, and discriminative image representation","volume":"58","author":"Tajbakhsh","year":"2019","journal-title":"Med Image Anal"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.17.19120","article-title":"Reply to \"Radiologic classification and imaging features of renal angiomyolipomas according to the amount of fat","volume":"210","author":"Park","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.11.6922","article-title":"Utility of iodine overlay technique and virtual unenhanced images for the characterization of renal masses by dual-energy CT","volume":"197","author":"Song","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-017-1224-9","article-title":"Effect of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: an evaluation based on tumor density","volume":"23","author":"Hatano","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-019-02093-6","article-title":"CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex","volume":"51","author":"Wang","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)61767-x","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13428","article-title":"Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex","volume":"24","author":"Hatano","year":"2017","journal-title":"Int J Urol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2018-000865","article-title":"Continuous low-dose everolimus shrinkage tuberous sclerosis complex-associated renal angiomyolipoma: a 48-month follow-up study","volume":"67","author":"Wei","year":"2019","journal-title":"J Investig Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv249","article-title":"Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial","volume":"31","author":"Bissler","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B40","doi-asserted-by":"publisher","first-page":"42470","DOI":"10.1038\/s41598-025-26541-9","article-title":"Spatial gene expression profiling reveals the distinct microenvironment of tuberous sclerosis complex-associated angiomyolipoma","volume":"15","author":"Watanabe","year":"2025","journal-title":"Sci Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3892\/ijo.2022.5422","article-title":"A multi-omics study of diagnostic markers and the unique inflammatory tumor micro-environment involved in tuberous sclerosis complex-related renal angiomyolipoma","volume":"61","author":"Wang","year":"2022","journal-title":"Int J Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0b013e3182815428","article-title":"Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma","volume":"80","author":"Krueger","year":"2013","journal-title":"Neurology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2006.02.003","article-title":"Large renal angiomyolipomas: digital subtraction angiographic grading and presentation with bleeding","volume":"61","author":"Rimon","year":"2006","journal-title":"Clin Radiol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1893155\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:48:12Z","timestamp":1784695692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1893155\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":45,"alternative-id":["10.3389\/fonc.2026.1893155"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1893155","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1893155"}}